{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:51:30Z","timestamp":1793987490557,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ijantimicag.2018.07.004","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T08:42:38Z","timestamp":1535704958000},"page":"443-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Evaluation of the efficacy and safety of ceftazidime\/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"52","author":[{"given":"Han","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Yuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zai-Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Chun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0001","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1001\/jama.2016.11764","article-title":"Antimicrobial resistance","volume":"316","author":"Marston","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0002","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12879-015-1054-1","article-title":"Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options","volume":"15","author":"Golan","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0003","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/cir202","article-title":"Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention","volume":"53","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0004","first-page":"44","article-title":"Carbapenemase-producing Enterobacteriaceae in the intensive care unit","volume":"5","author":"Rubio Lopez","year":"2017","journal-title":"Intensive Care Med Exp"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/21505594.2017.1292196","article-title":"Therapeutic options for carbapenem-resistant Enterobacteriaceae infections","volume":"8","author":"Trecarichi","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0006","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0007","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2147\/DDDT.S110946","article-title":"Ceftazidime\/avibactam: a novel cephalosporin\/non\u03b2-lactam \u03b2-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections","volume":"10","author":"Hidalgo","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0008","first-page":"e212","article-title":"A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline fosamil plus avibactam (CXL) administered by intravenous (IV) infusion to healthy subjects","volume":"32","author":"Riccobene","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0009","unstructured":"ClinicalTrials.gov. NCT01689207. To investigate the safety and tolerability of aztreonam\u2013avibactam (ATM-AVI). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01689207?term&NCT01689207&rank=1 [accessed 25 January 2018]."},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0010","unstructured":"ClinicalTrials.gov. NCT02655419. Determine the PK and safety and tolerability of ATM-AVI for the treatment of cIAIs in hospitalized adults (REJUVENATE). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02655419?term=NCT02655419&rank=1 [accessed 25 January 2018]."},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0011","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jiac.2015.04.006","article-title":"Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime\u2013avibactam in healthy Japanese volunteers","volume":"21","author":"Tominaga","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0012","first-page":"351","article-title":"Multi-drug resistant Gram-negative pathogens: ceftazidime\u2013avibactam is effective also in carbapenem-resistant pathogens","volume":"35","author":"Stiefelhagen","year":"2017","journal-title":"Arzneimitteltherapie"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0013","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s15010-017-1096-y","article-title":"Pharmacological aspects and spectrum of action of ceftazidime\u2013avibactam: a systematic review","volume":"46","author":"Tuon","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0014","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14787210.2018.1429912","article-title":"Novel \u03b2-lactam\/\u03b2-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials","volume":"16","author":"Chen","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1590\/1806-9282.64.03.253","article-title":"Efficacy and safety of ceftazidime\u2013avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): a meta-analysis of randomized controlled trials","volume":"64","author":"Zhang","year":"2018","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0016","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin vs. ceftazidime\u2013avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0017","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime\u2013avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0018","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime\u2013avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0019","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0020","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp [accessed 18 July 2018]."},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0021","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime\u2013avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0023","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0024","volume":"61","author":"Mendes","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0026","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1128\/AAC.01173-15","article-title":"\u03b2-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime\u2013avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates","volume":"60","author":"Mendes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0027","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime\u2013avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0028","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0029","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0030","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime\u2013avibactam versus imipenem\u2013cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0031","unstructured":"Brozek JAO, Sch\u00fcnemann H. GRADEpro [computer program]. Version 3.2 for Windows 2008."},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0032","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10096-011-1424-6","article-title":"Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study: healthcare-associated Gram-negative BSI","volume":"31","author":"Al-Hasan","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0033","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/520138","article-title":"Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis","volume":"29","author":"Echols","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0034","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/21505594.2016.1207834","article-title":"Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae","volume":"8","author":"Thaden","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel \u03b2-lactamase inhibitors: unlocking their potential in therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0036","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw143","article-title":"Optimal treatment for complicated intra-abdominal infections in the era of antibiotic resistance: a systematic review and meta-analysis of the efficacy and safety of combined therapy with metronidazole","volume":"3","author":"Mikamo","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11908-015-0510-9","article-title":"Carbapenem-resistant Enterobacteriaceae infections in children","volume":"18","author":"Chiotos","year":"2016","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0038","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/cid\/ciu052","article-title":"The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies","volume":"58","author":"Satlin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0039","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv050","article-title":"Treatment options for carbapenem-resistant Enterobacteriaceae infections","volume":"2","author":"Morrill","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0040","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/1469-0691.12697","article-title":"Treating infections caused by carbapenemase-producing Enterobacteriaceae","volume":"20","author":"Tzouvelekis","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0041","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/MRM.0000000000000106","article-title":"Carbapenemase inhibitors","volume":"28","author":"Aghamali","year":"2017","journal-title":"Rev Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0042","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem\u2013cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem\u2013vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0044","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jcph.793","article-title":"Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment","volume":"57","author":"Merdjan","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/17425255.2018.1434142","article-title":"Pharmacokinetic drug evaluation of avibactam\u202f+\u202fceftazidime for the treatment of hospital-acquired pneumonia","volume":"14","author":"Falcone","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0046","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.01330-10","article-title":"Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia","volume":"55","author":"Lodise","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0047","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cell.2016.09.032","article-title":"Empowering older antibiotics","volume":"167","author":"Wright","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0048","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40261-015-0347-x","article-title":"A randomized, phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime\u2013avibactam in healthy Chinese subjects","volume":"36","author":"Li","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0049","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0050","unstructured":"ClinicalTrials.gov. NCT01281462. Comparative study of coadministered ceftaroline fosamil and NXL104 vs. intravenous doripenem in adult subjects with complicated urinary tract infections. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01281462?term=NCT01281462&rank=1 [accessed 6 February 2018]."},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0051","unstructured":"ClinicalTrials.gov. NCT02497781. Evaluation of safety, pharmacokinetics and efficacy of ceftazidime and avibactam (CAZ-AVI) compared with cefepime in children from 3 months to less than 18 years of age with complicated urinary tract infections (cUTIs). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02497781?term=NCT02497781&rank=1 [accessed 6 February 2018]."},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0052","unstructured":"ClinicalTrials.gov. NCT02475733. Evaluation of safety, pharmacokinetics and efficacy of CAZ-AVI with metronidazole in children aged 3 months to 18 years old with complicated intra-abdominal infections (cIAIs). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02475733?term=NCT02475733&rank=1 [accessed 6 February 2018]."},{"key":"10.1016\/j.ijantimicag.2018.07.004_bib0053","unstructured":"ClinicalTrials.gov. NCT03329092. A study to determine the efficacy, safety and tolerability of aztreonam\u2013avibactam (ATM-AVI) \u00b1 metronidazole (MTZ) versus meropenem (MER) \u00b1 colistin (COL) for the treatment of serious infections due to Gram negative bacteria. (REVISIT). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03329092?term=NCT03329092&rank=1 [accessed 6 February 2018]."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791830195X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791830195X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:31:50Z","timestamp":1760376710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791830195X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S092485791830195X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.07.004","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the efficacy and safety of ceftazidime\/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}